Exxua Tablet, Extended Release
NDC 23594-151
Product Information
Exxua (gepirone) is a NDA-approved product labeled by Aytu Therapeutics, Llc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a pink tablet, extended release for oral administration. This product entry covers the primary NDC 23594-151 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
WHITE (C48325 - OFF-WHITE)
FK;1
FK;7
Code Structure Chart
Product Details
What is NDC 23594-151?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- GEPIRONE HYDROCHLORIDE (UNII: 80C9L8EP6V)
- GEPIRONE (UNII: JW5Y7B8Z18) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)
- FERRIC OXIDE YELLOW (UNII: EX438O2MRT)
- FERRIC OXIDE RED (UNII: 1K09F3G675)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2672372 - gepirone 18.2 MG 24HR Extended Release Oral Tablet
- RxCUI: 2672372 - 24 HR gepirone 18.2 MG Extended Release Oral Tablet
- RxCUI: 2672372 - gepirone 18.2 MG (equivalent to 20 MG gepirone hydrochloride) 24 HR Extended Release Oral Tablet
- RxCUI: 2672379 - EXXUA 18.2 MG 24HR Extended Release Oral Tablet
- RxCUI: 2672379 - 24 HR gepirone 18.2 MG Extended Release Oral Tablet [Exxua]
* Please review the full disclaimer at the bottom of this page.